Live feed08:30:00·2011dPRReleasevia QuantisnowZymeworks Receives FDA Breakthrough Therapy Designation for HER2-Targeted Bispecific Antibody Zanidatamab in Patients with Biliary Tract CancerByQuantisnow·Wall Street's wire, on your screen.ZYME· Zymeworks Inc.Health CareOriginal source
